Everest Medicines Limited 1952.HK Stock

Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include 9 clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. The company offers Nefecon, an oral formulation of budesonide for the treatment of primary immunoglobulin nephropathy (IgAN); EVER001, a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor which is in the phase 1b/2 clinical trial for the treatment of renal diseases; PTX-COVID19-B, a lipid nanoparticle-formulated mRNA COVID-19 vaccine; EVER-COVID19-M1, an Omicron-targeting bivalent COVID-19 booster vaccine; and mRNA rabies vaccine. Further, its pipeline includes Eravacycline, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; EVER206, a polymyxin derivative designed to reduce toxicity and nephrotoxicity which is in phase 1 of clinical trial; and FGF401 is an ATP-competitive, reversible-covalent inhibitor of FGFR4 which is in phase 1/2 of clinical trial. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.